x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DMM-001127
| Status | Age | Sex |
|---|---|---|
|
|
|
| Product Overview | |
|---|---|
| Model Description | These mice carry loxP sites flanking exon 3-4 of Igf2bp2 gene. When crossed with a Cre recombinase-expressing strain, this strain is useful in eliminating tissue-specific conditional expression of Igf2bp2 gene. |
| Strain Name | C57BL/6J-Igf2bp2em1(flox) |
| Background Strain | C57BL/6J |
| SPF | Yes |
| Research Application | Related research on gene expression and MAPK-Erk pathway. |
| Target Information | |
|---|---|
| Target Name | Igf2bp2 |
| Synonyms | Imp2, IMP-2, Neilsen, C330012H03Rik |
| Gene ID | 319765 |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
